Gts Securities LLC Cassava Sciences Inc Call Options Transaction History

Gts Securities LLC

  • $46.5 Billion
  • Q2 2024

Call Options

4 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 14, 2024
BUY
$12.35 - $26.11 $29,640 - $62,664
2,400 Added 4.16%
60,100 $742,000
Q1 2024

May 15, 2024
SELL
$18.44 - $26.41 $1.16 Million - $1.66 Million
-62,900 Reduced 52.16%
57,700 $1.17 Million
Q4 2023

Feb 14, 2024
SELL
$12.64 - $30.11 $308,416 - $734,684
-24,400 Reduced 16.83%
120,600 $2.71 Million
Q3 2023

Nov 15, 2023
BUY
$16.64 - $25.32 $2.41 Million - $3.67 Million
145,000 New
145,000 $2.41 Million

Others Institutions Holding SAVA

# of Institutions
184
Shares Held
13.3M
Call Options Held
1.38M
Put Options Held
2.04M
View Full List

About CASSAVA SCIENCES INC

SAVA Quotes by TradingView
  • Ticker SAVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,097,900
  • Market Cap $1.14B
  • Description
  • Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...
More about SAVA
Track This Portfolio

Track Gts Securities LLC Portfolio

Follow Gts Securities LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gts Securities LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gts Securities LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email